-+ 0.00%
-+ 0.00%
-+ 0.00%

Processa R&D President David Young acquires 1,706 shares for $4,589.14

PUBT·05/01/2026 20:40:30
Listen to the news
Processa R&D President David Young acquires 1,706 shares for $4,589.14
  • Processa Pharmaceuticals director David Young, President of Research & Development, reported purchase of 1,706 common shares at USD 2.69.
  • Directly held common shares increased to 13,813.
  • Indirect holdings totaled 2,416 common shares, held via trust, family entities, CorLyst.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Processa Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000897069-26-001010), on May 01, 2026, and is solely responsible for the information contained therein.